Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Arcellx, Inc. ACLX
$40.70
-$3.53 (-8.68%)
На 18:05, 12 мая 2023
-12.16%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
2137987476.00000000
-
week52high
45.05
-
week52low
6.04
-
Revenue
0
-
P/E TTM
-8
-
Beta
0.00000000
-
EPS
-5.10000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 04:00
Описание компании
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Canaccord Genuity | Buy | 20 июл 2022 г. | |
| SVB Leerink | Outperform | Outperform | 23 июн 2022 г. |
| SVB Leerink | Outperform | Outperform | 13 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 29 мар 2022 г. |
| SVB Leerink | Outperform | 01 мар 2022 г. | |
| Needham | Buy | 27 окт 2022 г. | |
| Guggenheim | Buy | 31 окт 2022 г. | |
| Needham | Buy | Buy | 12 дек 2022 г. |
| Barclays | Overweight | Overweight | 12 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Elghandour Rami | A | 159292 | 159292 | 03 янв 2023 г. |
| Elghandour Rami | A | 245065 | 245065 | 03 янв 2023 г. |
| Gilson Michelle | A | 46018 | 46018 | 03 янв 2023 г. |
| Gilson Michelle | A | 70796 | 70796 | 03 янв 2023 г. |
| Heery Christopher | D | 250205 | 2500 | 03 янв 2023 г. |
| Heery Christopher | D | 49558 | 49558 | 03 янв 2023 г. |
| Heery Christopher | D | 76242 | 76242 | 03 янв 2023 г. |
| Heery Christopher | D | 0 | 2500 | 03 янв 2023 г. |
| Heery Christopher | A | 2500 | 2500 | 03 янв 2023 г. |
| SANDELL SCOTT D | D | 0 | 195 | 23 дек 2022 г. |
Новостная лента
Arcellx: The Gilead Deal Derisks And Proves Their Technology
Seeking Alpha
09 янв 2023 г. в 12:46
Arcellx, Inc. produced excellent data for their ddBCMA program. The data helped clinch a deal with Gilead.
Arcellx flies on $325M deal with Gilead's Kite for multiple myeloma treatment
Proactive Investors
09 дек 2022 г. в 11:42
Arcellx shares soared in early trade after the clinical-stage biotechnology company announced a global strategic collaboration with Gilead Sciences' Kite to co-develop and co-commercialize its late-stage product candidate, CART-dddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.
Why Is Arcellx (ACLX) Stock Up 25% Today?
InvestorPlace
09 дек 2022 г. в 11:26
Investors of Arcellx (NASDAQ: ACLX ) stock are in a great mood today, and the reason is no mystery. Acrellx just disclosed that it's teaming with biopharmaceutical giant Gilead Sciences (NASDAQ: GILD ).
Gilead to co-develop Arcellx's multiple myeloma drug
Market Watch
09 дек 2022 г. в 08:46
Gilead Sciences Inc. GILD, +1.91% said Friday that it will co-develop and co-commercialize Arcellx Inc.'s ACLX, +7.22% multiple myeloma treatment candidate, which is currently in Phase 2 clinical trials. Gilead will pay Arcellx $225 million upfront, plus make a $100 million equity investment in the company.
These Are the 10 Best-Performing IPOs in 2022 Through October
24/7 Wall Street
16 ноя 2022 г. в 21:21
The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.